Manuscript type: Original Article

DOI: 10.5152/TurkThoracJ.2019.180136

Title: THERAPEUTIC TREATMENT WITH MESENCHYMAL CELLS ISOLATED FROM
ABDOMINAL ADIPOSE TISSUE DOES NOT PREVENT ELASTASE-INDUCED EMPHYSEMA IN
THE RAT

Short Title: The effect of Mesenchymal cells on COPD

Authors: Pınar Yıldız Gülhan¹, Mehmet Savaş Ekici², Mehmet Niyaz³, Muhammet Gülhan⁴, Mustafa Emre Erçin⁵, Aydanur Ekici², Nurkan Aksoy⁶

Instutions: ¹Düzce University, Faculty of Medicine, Department of Chest Diseases, Düzce, Turkey

²Kırıkkale University, Faculty of Medicine, Department of Chest Diseases, Kırıkkale, Turkey

³Bartin State Hospital, Department of Cardiovascular Surgery, Bartin, Turkey

⁴Tosya State Hospital, Department of Infectious Diseases and Clinical Microbiology, Kastamonu, Turkey

⁵Karadeniz Technical University, Faculty of Medicine, Department of Pathology, Trabzon, Turkey

⁶Yenimahalle State Hospital, Department of Biochemistry, Ankara, Turkey

Address for correspondence: Pinar Yildiz Gülhan, Düzce University, Faculty of Medicine, Department of Chest Diseases, Düzce, Turkey

E-mail: pinaryildiz691@hotmail.com

Received: 15.08.2018

Accepted: 06.02.2019

Cite this article as: Yıldız Gülhan P, Ekici MS, Niyaz M, et al. THERAPEUTIC TREATMENT WITH MESENCHYMAL CELLS ISOLATED FROM ABDOMINAL ADIPOSE TISSUE DOES NOT PREVENT ELASTASE-INDUCED EMPHYSEMA IN THE RAT. Turk Thorac J 2019; DOI: 10.5152/TurkThoracJ.2019.180136

ABSTRACT

Background: Emphysema and chronic bronchitis have different pathophysiology but are both significant components of chronic obstructive lung disease (COPD). The levels of matrix metalloproteinase (MMP-9) in bronchoalveloar lavage fluid (BALF) and in serum are associated with emphysema. Intratracheal admnistration of elastase has been used to create a rat model of emphysema. Adipose tissue-derived mesenchymal stem cells (MSC) have been postulated to prevent or reverse emphysema but this has not been examined in the rat moel of elastase-induced emphysema.

Methods: In this study, 6/8- week-old 31 Wistar albino rats weighing between 250-300 g were assessed. On day 1 animals were treated intratracheally with 0.5 mls saline (Controls, n=10); 0.5 ml saline solution containing 0.1 IU porcine pancreatic elastase (PPE) This article has been accepted for publication and undergone full peer review but has not been through the copyediting, typesetting, pagination and proofreading process, which may lead to differences between this version and the Version of Record. Please cite this article as: Yıldız Gülhan P, Ekici MS, Niyaz M, et al. THERAPEUTIC TREATMENT WITH MESENCHYMAL CELLS ISOLATED FROM ABDOMINAL ADIPOSE TISSUE DOES NOT PREVENT ELASTASE-INDUCED EMPHYSEMA IN THE RAT. Turk Thorac J 2019; DOI: 10.5152/TurkThoracJ.2019.180136

per animal (Elastase group, n=12) or PPE plus MSC (Elastase-MSC group, n=9). MSCs suspended in serum were injected via the caudal vein at day 21. At least 10⁶ cell were injected. All animals were sacrificed on day 42 and the emphysema index (EI) was calculated and BALF and serum MMP-9 concentrations measured.

Results: PPE induced a significant degree of emphysema compared to controls as determined by the EI index (p=0.008). This was not reversed by MSC treatment and the EI remained significantly reduced compared to controls (p=0.001) and no different from Elastase-treated animals. There was no statistically significant difference between serum and BALF MMP-9 levels between the control and treatment groups.

Conclusions: Our findings suggest that therapeutic treatment with adipose tissuederived MSC in rats has no effect on emphysema or on MMP9 expression, a marker of emphysema.

Key Words: Chronic obstructive pulmonary disease, emphysema, mesenchymal cell, matrix metalloprotein.

INTRODUCTION

According to the GOLD 2017 Guidelines, COPD is a common, preventable, and treatable disease caused by exposure to damaging particles or gasses and is characterized by permanent airway obstruction and respiratory symptoms (1). Both emphysema and chronic bronchitis are the important components of COPD although they are associated with distinct pathophysiological mechanisms. These pathophysiological mechanisms include a protease-antiprotease imbalance which causes matrix damage and emphysema; oxidative stress which drives inflammatory cell migration and protein oxidation; alveolar matrix destruction and disturbed regenerative capacity in the small airways, as well as excessive matrix accumulation in the arteries, leading to pulmonary hypertension; and endothelial and epithelial cell apoptosis (2, 3).

COPD treatment mainly targets symptoms but these medications are not curative (4). Mesenchymal stem cells (MSCs) have been proposed as candidate treatment in a variety of diseases due to their characteristics, including easy of isolation; their ability to replicate in large numbers under culture environments; their capacity to differentiate and possess immunosuppressive characteristics and their ability to migrate areas of cellular damage (5). Previous therapeutic studies in rat emphysema models have provided evidence that MSCs are protective against the development of emphysema (6, 7).

Autologous MSCs can be readily isolated from the bone marrow and other tissues and have been shown to reduce inflammation and contribute to the repair process in several disease models (5). The use of MSCs, alone or in combination with novel bioengineering approaches, may therefore have therapeutic potential for pulmonary repair and remodelling This article has been accepted for publication and undergone full peer review but has not been through the copyediting, typesetting, pagination and proofreading process, which may lead to differences between this version and the Version of Record. Please cite this article as: Yıldız Gülhan P, Ekici MS, Niyaz M, et al. THERAPEUTIC TREATMENT WITH MESENCHYMAL CELLS ISOLATED FROM ABDOMINAL ADIPOSE TISSUE DOES NOT PREVENT ELASTASE-INDUCED EMPHYSEMA IN THE RAT. Turk Thorac J 2019; DOI: 10.5152/TurkThoracJ.2019.180136

(5). Indeed, a recent phase II clinical study was conducted with MSCs in patient with mild and modarate COPD (9). MSCs has been evaluated in several therapeutic models of severe pulmonary diseases including acute pulmonary injury (10), COPD (11), pulmonary hypertension (12), asthma (13), and lung fibrosis (14). In experimental models, MSCs have been applied to the lungs via both intravenous and intratracheal routes. Improvements in the pulmonary damage have been demonstrated by administering the endogenous pulmonary stem cells with MSC phenotype to the rat lungs treated by elastase (11).

This study demonstrated a reduction in the inflammatory response by the MSCs and that the MSC treatment was safe in COPD patients, however, no beneficial effects were observed in pulmonary functions.

We hypothesized that MSCs will attenuate emphysema and decrease the levels of bronchoalvelar lavage fluid (BALF) and serum MMP-9, in a rat model of elastase-induced emphysema. The specific aim was to assess the therapeutic potential of adipose tissuederived MSCs and the effect on MMP-9 expression as this would be more akin to the approach required to treat COPD patients.

MATERIALS and METHODS

The current study was approved by the Ethics Committee of University (Ethics Committee No: 2011/121) and performe in the Animal Laboratories of University between April-May 2010. All procedures were carried out in compliance with the Declaration of Helsinki (1986).

Isolation of the Adipose Tissue Mesenchymal Stem Cells

MSCs were isolated from subcutaneous adipose tissue in the flanks of the rats (Wistar albino, 6-8 week old male rats, 300 g). MSCs were characterised using immunofluorescence staining and flow cytometric analysis as described below.

Characterization of MSCs by Immunofluorescence Staining

The expression of two MSC-selective surface antigens CD13 and CD29 was analysed using immunofluorescence staining.

Flow cytometric analyses of CD29, CD45, CD54, CD90, CD106, MHC Class I and MHC Class II cell surface markers was performed within the Center for Stem Cell and Gene Therapies Research and Application Center of xxxx University (SCGTR, xxx, Turkey) as previously described (Figure 2).

Study design

34 Wistar albino rats weighing 250-300g were divided into three groups. Animals were anaethetised with ketamine (100 mg/kg; intraperitoneally) before vehicle (5% Gummi Arabicum adhesive [Arabic Gum]) (n=10) or porcine pancreatic elastase (PPE, CALBIOCHEM,

EMD Biosciences Inc., CA) were delivered via the intratracheal route as previously described (15). The vehicle solution was administered one hour prior to the treatment with PPE (0.1 IU/g of body weight in 0.5ml saline)(n=13). PPE solutions in saline were freshly prepared under sterile conditions just before use. Rats were placed in the Trendelenburg position to enable the even distribution of elastase into both lungs. The number of the rats with postelastase lethality in the Elastase and Elastase MSC groups were n=1 and n=2, respectively.

On the 21st day of the study, 1x10⁶ MSCs suspended in physiological saline solution was administered to the Elastase-MSC Group (n=11) via the tail veins. On day 42 of the study, all rats in the three groups were sacrificed under high-dose ketamine (100 mg/kg) anaesthesia.

Bronchoalveolar lavage (BAL) was performed immediately after the rats were sacrificed and the trachea was ligated from the upper end as described previously (16). BALF was collected using 3x 3ml saline washes delivered via a tracheal cannulae. The pooled BALF was cooled and centrifuged at 1500 rpm for 5 min and the supernatant kept for MMP-9 analysis.

BALF and Serum MMP-9 Analysis

BALF and serum MMP-9 levels were measured by commercially available ELISA kits as recommended by the manufacturer (Med-Systems Diagnostics Gmbh, Vienna, Austria).

Histological Analysis of The Lung

The right and left lungs of the rats were taken out after sacrifice and fixed in 10% formaldehyde. Lung tissues were divided into 2-mm-thick blocks and embedding in paraffin and 5 µm tissue slices cut and stained with hematoxylin-eosin before being examined under the light microscope (17). 5 random photographs of each slide were obtained and an emphysema index (EI) calculated using the following formula (Prof. Dr Önder Bozdoğan et al., Kırıkkale Pathology AD.): Emphysema Index = (Emphysema area + Normal area) / (Emphysema area + Normal area + Stromal field).

Statistical Analyses

All data were analyzed using "Statistical Packages for the Social Science" (SPSS) 11.5. After performing the descriptive statistical analyzes (frequency, percentage distribution, mean ± standard deviation, median [minimum-maximum]), the Kruskal Wallis Analysis of Variance Test was applied. When the results show significant differences among the groups, the Mann-Whitney U test was used. The association between continuous variables was evaluated by the Spearman's Correlation Test. A value of p≤0.005 was considered to be statistically significant.

RESULTS:

A statistically significant difference was found in the median Emphysema Index (EI) values among the three rat groups in the study (p = 0.005)(Figure 3a-c)(Table 1). The median EI of both the Elastase (p=0.008) and Elastase-MSC (p = 0.001) groups were significantly lower than that of the control group. Therapeutic administration of MSCs had no effect on EI.

There were no statistically significant differences in BALF or serum MMP-9 levels between the three groups (**Table 1**).

		Eİ (%)	Serum MMP-9	BAL MMP-9			
	Mean	76.75	5.60	5.11			
	SD	5.57	1.07	0.08			
Elastase (n=12)	Median	76.45	5.19	5.09			
	Min.	69.50	5.08	5.02			
	Max	87.30	8.85	5.31			
Elastase-MSC (n=9)	Mean	76.22	5.29	5.09			
	SD	6.13	0.26	0.03			
	Median	77.60	5.23	5.08			
	Min.	61.70	5.06	5.04			
	Max	84.30	5.95	5.13			

Control (n=10)	Mean	82.94	5.52	5.11
	SD	2.83	0.19	0.04
	Median	84.00	5.42	5.10
	Min.	78.70	5.36	5.06
	Max	85.60	5.84	5.16
P value		0.005*	0.018+	0.742

When all rats included in the study were evaluated together; no significant associations were observed between the EI values and the serum levels of MMP-9 (r=0.205, p=0.269); between the EI values and the BAL MMP-9 levels (r=-0.069, p=0.712) and between serum MMP-9 levels (r=0.184, p=0.323) and the BAL MMP-9 levels (**Table 2**).

		EI	Serum MMP-9
Serum MMP-9	r	0.205	
Seruiii iviivir-9	р	0.269	
BAL MMP-9	r	-0.069	0.184
	р	0.712	0.323

When rats in the Elastase Group alone were evaluated; no statistically significant associations were detected between the El and serum MMP-9 (r=0.214, p=0.505) levels; between the El and BAL MMP-9 (r=-0.260, p=0.414) levels; and between the serum MMP-9 (r 0.030, p=0.926) and BAL MMP-9 levels (**Table 3**).

		EI	Serum MMP-9
Serum MMP-9	r	0.214	
	р	0.505	
BAL MMP-9	r	-0.260	0.030

_		
р	0.414	0.926

When the rats in the Elastase-MSE Group were evaluated; no significant associations were observed between the El levels and serum MMP-9 (r=-0.628, p=0.070) levels; between the El and BAL MMP-9 (r=-0.380, p=0.313) levels; between the serum MMP-9 levels (r=0.470, p=0.201) and BAL MMP-9 levels (**Table 4**).

		EI	Serum MMP-9
Serum MMP-9	r	-0.628	
	р	0.070	
BAL MMP-9	r	-0.380	0.470
	р	0.313	0.201

Finally, there was no correlation between EI and serum or BAL MMP-9 in the Control Group alone.(**Table 5**).

		EI	Serum MMP-9
Serum MMP-9	r	-0.600	
	р	0.067	
BAL MMP-9	r	0.200	-0.600
	р	0.580	0.067

There were no statistically significant differences between the baseline body weight (BW) (p=0.119) values and the BW change values (p=0.153) in the three rat groups in the study (Figure 4).

DISCUSSION

In this study we confirmed the ability of PPE to induce significant levels of emphysema in the rat. Contrary to expectations, we did not show any effect of therapeutic administration of adipose tissue-derived MSCs on PPE-induced emhysema as determined histologically. In addition, we were unable to demonstrate any correlation of the degree of emphysema with blood or BALF levels of MMP-9. Previous studies have shown that a single-dose of intratracheal PPE results in the airspace enlargement similar to emphysema-like lesions (18,19,) and that degree of emphysema is enhanced with repeated PPE doses (20).

Mesenchymal stem cells (MSCs) have been proposed as potential candidates for the treatment of many diseases (5). Previous studies in rat models of emphysema have provided evidence that prophylactic therapy with MSCs provides protection against the development of emphysema (6,7). In addition, MSCs suppress inflammation in animal models of acute pulmonary injury (21-23) and partially improve pulmonary emphysema in papain or elastin-induced animal (mice and rat) emphysema models (24-26). Intrapulmonary therapeutic administration of rat MSCs to rats chronically exposed to cigarette smoke is also protective against emphysema (27). However, although these reports indicate success using prophylactic interventions or study using adipose tissue-derived MSCs, a promising option in cell therapy (28), provided no regression in the emphysema areas induced by PPE. One limitation of our study was that we did not perform immunohistochemical evaluation of the presence of adipose tissue-derived MSCs in the lung tissue. A failure of these cells to migrate to the lung could account for the lack of effect seen although other studies have reported efficient targeting of the lung by MSCs injected into the rat tail vein (29).

The proposed use of MSCs in the treatment of pulmonary diseases such as acute lung injury, pulmonary fibrosis, and COPD is based on the capacity of these cells to modulate local inflammatory and immunological responses (30). A phase II, multicenter, randomized, placebo-controlled study using allogeneic MSCs in patients with moderate to severe COPD demonstrated that this therapy was safe and that the MSC infusion gave a significant reduction in the CRP levels (31). Monthly systemic MSC infusion in these COPD patients had no effect on adverse events but did not reduce exacerbation frequency or the course of disease (32). In contrast, bone marrow-derived stem cells were infused systemically into 4 patients with COPD/pulmonary emphysema and grade IV dyspnea and gave a slight improvement in spirometry over a 12-month period (33).

Autologous lung-derived MSCs are also considered to have potential beneficial effects in the treatment of pulmonary emphysema (34). These were shown to be safe in a small (10 patients) phase 1 clinical trial in GOLD stage 3-4 COPD patients when used as an add-on treatment to one-way endobronchial valves (EBV). Allogeneic bone marrow-derived MSCs (10⁸ cells) were given just before the insertion of one-way EBVs and no adverse effects were seen after 90 days (35).

MMP-9 levels are increased in the lungs (36) and alveolar macrophages (37,38) of patients with COPD. MMP-9 production is further increased in circulating monocytes of individuals with advanced emphysema (39). However, in a study of 101 patients with emphysema, although BALF MMP levels were higher in emphysema patients compared to non-smoking controls, MMP-9 did not predict severity or progression of emphysema due to elevated levels also being seen in the healthy smoking control group (40). In addition, the

release of MMP-9 from serum platelets or leukocytes is enhanced upon sampling and measured serum MMP-9 levels may not accurately reflect circulating MMP-9 concentrations (41-42). Accumulation of MMP-9 expressing pulmonary alveolar macrophages has been reported to accompany the development of emphysema in the mouse intraperitoneral PPE-induced emphysema model (43). In contrast, we did not show any link between BALF or serum levels of MMP-9 and emphysema scores in our rat model after 6 weeks. A limitation of our study was that we did not examine the time-course of BALF or serum MMP-9 expression in our model and we may have missed the optimal time point for this analysis.

Loss of body and muscle mass in COPD (pulmonary cachexia) causes skeletal muscle weakness and impaired exercise capacity (44,45). The association of the pulmonary cachexia to pulmonary inflammation (46) and the increased levels of circulating inflammatory cytokines (47-49) suggests that systemic inflammations may trigger or contribute to muscle atrophy (50). These systemic abnormalities can also be mimicked by PPE administration in animal models of emphysema (20, 51-53). Although weight gain was the lowest in rats in the Elastase Group, consistent with the literature, this did not reach statistical significance.

6. CONCLUSIONS AND RECOMMENDATIONS

The results of our study demonstrated that the emphysematous areas of the Elastase and Elastase-MSC Groups were larger compared to the Control Group and that the serum and BALF MMP-9 levels were similar in the three groups of animals.

Although evidence in previous animal models of emphysema indicated that prophylactic MSCs prevent the onset or development of emphysema, our results indicate

that therapeutic administration of adipose tissue-derived MSCs are ineffective at reversing emphysema. Our results fit with the overall safety and efficacy profile of therapeutic MSC infusion in COPD patients but future studies should examine the presence of these MSCs in lung tissue to assess whether sufficient MSCs reached the lung tissue to have an effect on emphysema.

Our data on BALF and serum MMP-9 levels were in part agreement with the literature in general. However, our findings regarding the effect of MSCs on MMP-9 levels paralleled our findings on emphysema with no observed effect.

Overall, our data does not support the therapeutic benefit of adipose tissue-derived MSCs for the treatment of emphysema in COPD patients.

REFERENCES

- Global Initiative for Chronic Obstructive Lung Disease (GOLD). Global Strategy for the Diagnosis, Management and Prevention of COPD (Updated 2017). In; 2017.
- Kasahara Y, Tuder RM, Cool CD, et al. Endothelial cell death and decreased expression of vascular endothelial growth factor and vascular endothelial growth factor receptor 2 in emphysema. Am J Respir Crit Care Med 2001;163(3 Pt 1):737-44.
- 3. Voelkel NF, Gomez-Arroyo J, Mizuno S. COPD/emphysema: The vascular story. Pulm Circ 2011;1(3):320-6.
- Cheng SL, Lin CH, Yao CL. Mesenchymal Stem Cell Administration in Patients with Chronic Obstructive Pulmonary Disease: State of the Science. Stem Cells Int. 2017;2017:8916570. doi: 10.1155/2017/8916570. Epub 2017 Feb 20.
- 5. Salem HK, Thiemermann C. Mesenchymal stromal cells: current understanding and clinical status. Stem Cells 2010;28(3):585-96.
- 6. Zhen G, Liu H, Gu N, et al. Mesenchymal stem cells transplantation protects against rat pulmonary emphysema. Front Biosci 2008;13:3415-22.
- 7. Liu HM, Zhen GH, Zhang ZX, et al. [Effects of bone marrow mesenchymal stem cells transplantation on the apoptosis of alveolar wall cells in papain and Co60-induced pulmonary emphysema rats]. Zhongguo Ying Yong Sheng Li Xue Za Zhi 2008;24(2):210-4.
- 8. Wagner DE, Cardoso WV, Gilpin SE, et al. ATS Subcommittee on Stem Cells and Cell Therapies. An Official American Thoracic Society Workshop Report 2015. Stem Cells and

- Cell Therapies in Lung Biology and Diseases. Ann Am Thorac Soc. 2016 Aug;13(8):S259-78.
- 9. Osiris. Osiris Therapeutics Reports interim data for COPD stem cell study 2009. In; 2012.
- 10. Matthay MA, Thompson BT, Read EJ, et al. Therapeutic potential of mesenchymal stem cells for severe acute lung injury. Chest;138(4):965-72.
- 11. Cho RJ, Kim YS, Kim JY et al. Human adipose-derived mesenchymal stem cell spheroids improve recovery in a Mouse model of elastase-induced emphysema. BMB Rep. 2017; 50(2): 79-84.
- 12. Baber SR, Deng W, Master RG, et al. Intratracheal mesenchymal stem cell administration attenuates monocrotaline-induced pulmonary hypertension and endothelial dysfunction. Am J Physiol Heart Circ Physiol 2007;292(2):H1120-8.
- 13. Weiss DJ, Kolls JK, Ortiz LA, et al. Stem cells and cell therapies in lung biology and lung diseases. Proc Am Thorac Soc 2008;5(5):637-67.
- 14. Rojas M, Xu J, Woods CR, et al. Bone marrow-derived mesenchymal stem cells in repair of the injured lung. Am J Respir Cell Mol Biol 2005;33(2):145-52.
- 15. van de Lest CH, Versteeg EM, Veerkamp JH, et al. Digestion of proteoglycans in porcine pancreatic elastase-induced emphysema in rats. Eur Respir J 1995;8(2):238-45.
- 16. Wang YH, Bai CX, Hong QY, et al. Anti-inflammatory effect of methoxyphenamine compound in rat model of chronic obstructive pulmonary disease. Acta Pharmacol Sin 2003;24(12):1324-7.

- 17. Finsnes F, Skjonsberg OH, Tonnessen T, et al. Endothelin production and effects of endothelin antagonism during experimental airway inflammation. Am J Respir Crit Care Med 1997;155(4):1404-12.
- 18. Ishizawa K, Kubo H, Yamada M, et al. Bone marrow-derived cells contribute to lung regeneration after elastase-induced pulmonary emphysema. FEBS Lett 2004;556(1-3):249-52
- 19. Kawakami M, Matsuo Y, Yoshiura K, et al. Sequential and quantitative analysis of a murine model of elastase-induced emphysema. Biol Pharm Bull 2008;31(7):1434-8.
- 20. Luthje L, Raupach T, Michels H, et al. Exercise intolerance and systemic manifestations of pulmonary emphysema in a mouse model. Respir Res 2009;10:7.
- 21. Gupta N, Su X, Popov B, et al. Intrapulmonary delivery of bone marrow-derived mesenchymal stem cells improves survival and attenuates endotoxin-induced acute lung injury in mice. J Immunol 2007;179(3):1855-63.
- 22. Xu J, Woods CR, Mora AL, et al. Prevention of endotoxin-induced systemic response by bone marrow-derived mesenchymal stem cells in mice. Am J Physiol Lung Cell Mol Physiol 2007;293(1):L131-41.
- 23. Song L, Xu J, Qu J, et al. A therapeutic role for mesenchymal stem cells in acute lung injury independent of hypoxia-induced mitogenic factor. J Cell Mol Med 2012;16(2):376-85.
- 24. Zhen G, Xue Z, Zhao J, et al. Mesenchymal stem cell transplantation increases expression of vascular endothelial growth factor in papain-induced emphysematous lungs and inhibits apoptosis of lung cells. Cytotherapy 2010;12(5):605-14.

- 25. Katsha AM, Ohkouchi S, Xin H, et al. Paracrine factors of multipotent stromal cells ameliorate lung injury in an elastase-induced emphysema model. Mol Ther 2011;19(1):196-203.
- 26. D'Agostino B, Sullo N, Siniscalco D, et al. Mesenchymal stem cell therapy for the treatment of chronic obstructive pulmonary disease. Expert Opin Biol Ther 2010;10(5):681-7.
- 27. Guan XJ, Song L, Han FF, et al. Mesenchymal stem cells protect cigarette smoke-damaged lung and pulmonary function partly via 29. Sun CK, Yen CH, Lin YC, Tsai TH, Chang LT, Kao YH, et al. Autologous transplantation of adipose-derived mesenchymal stem cells markedly reduced acute ischemia-reperfusion lung injury in a rodent model. J Transl Med 2011;9:118.
- 28. VEGF-VEGF receptors. J Cell Biochem 2013;114(2):323-35.
- 29. Sammour I, Somashekar S, Huang J, et al. The Effect of Gender on Mesenchymal Stem Cell (MSC) Efficacy in Neonatal Hyperoxia-Induced Lung Injury. PloS One 2016Oct 6;11 (10):e0164269 doi: 10.1371/journal pone.0164269.
- 30. Sueblinvong V, Weiss DJ. Cell therapy approaches for lung diseases: current status. Curr Opin Pharmacol 2009;9(3):268-73.
- 31. Iyer SS, Co C, Rojas M. Mesenchymal stem cells and inflammatory lung diseases.

 Panminerva Med 2009;51(1):5-16.
- 32. Weiss DJ, Casaburi R, Flannery R, et al. A Placebo-Controlled Randomized Trial of Mesenchymal Stem Cells in Chronic Obstructive Pulmonary Disease. Chest 2012.


- 33. Ribeiro-Paes JT, Bilaqui A, Greco OT, et al. Unicentric study of cell therapy in chronic obstructive pulmonary disease/pulmonary emphysema. Int J Chron Obstruct Pulmon Dis 2011;6:63-71.
- 34. Ingenito EP, Tsai L, Murthy S, et al. Autologous lung-derived mesenchymal stem cell transplantation in experimental emphysema. Cell Transplant 2012;21(1):175-89.
- 35. de Oliveira HG, Cruz FF, Antunes MA, et al. Combined Bone Marrow-Derived Mesenchymal Stromal Cell Therapy and One-Way Endobronchial Valve Placement in Patients with Pulmonary Emphysema: A Phase I Clinical Trial. Stem Cells Transl Med. 2017 Mar;6(3):962-969. doi: 10.1002/sctm.16-0315. Epub 2016 Dec 9.
- 36. Ohnishi K, Takagi M, Kurokawa Y, et al. Matrix metalloproteinase-mediated extracellular matrix protein degradation in human pulmonary emphysema. Lab Invest 1998;78(9):1077-87.
- 37. Russell RE, Culpitt SV, DeMatos C, et al. Release and activity of matrix metalloproteinase-9 and tissue inhibitor of metalloproteinase-1 by alveolar macrophages from patients with chronic obstructive pulmonary disease. Am J Respir Cell Mol Biol 2002;26(5):602-9.
- 38. Finlay GA, O'Driscoll LR, Russell KJ, et al. Matrix metalloproteinase expression and production by alveolar macrophages in emphysema. Am J Respir Crit Care Med 1997;156(1):240-7.
- 39. Atkinson JJ, Lutey BA, Suzuki Y, et al. The role of matrix metalloproteinase-9 in cigarette smoke-induced emphysema. Am J Respir Crit Care Med 2011;183(7):876-84.

- 40. D'Armiento JM, Goldklang MP, Hardigan AA, et al. Increased Matrix Metalloproteinase (MMPs) Levels Do Not Predict Disease Severity or Progression in Emphysema. PLoS One 2013;8(2):e56352.
- 41. Jung K, Lein M, Laube C, et al. Blood specimen collection methods influence the concentration and the diagnostic validity of matrix metalloproteinase 9 in blood. Clin Chim Acta 2001;314(1-2):241-4.
- 42. Jung K, Lein M, Roemer A, et al. Circulating gelatinase B (MMP-9)--the impact of the preanalytical step of blood collection. Matrix Biol 2002;21(5):381-2.
- 43. Ishikawa T, Aoshiba K, Yokohori N, et al. Macrophage colony-stimulating factor aggravates rather than regenerates emphysematous lungs in mice. Respiration 2006;73(4):538-45.
- 44. Schols AM, Slangen J, Volovics L, et al. Weight loss is a reversible factor in the prognosis of chronic obstructive pulmonary disease. Am J Respir Crit Care Med 1998;157(6 Pt 1):1791-7.
- 45. Bolton CE, Ionescu AA, Shiels KM, et al. Associated loss of fat-free mass and bone mineral density in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2004;170(12):1286-93.
- 46. Keatings VM, Collins PD, Scott DM, et al. Differences in interleukin-8 and tumor necrosis factor-alpha in induced sputum from patients with chronic obstructive pulmonary disease or asthma. Am J Respir Crit Care Med 1996;153(2):530-4.

- 47. Eid AA, Ionescu AA, Nixon LS, et al. Inflammatory response and body composition in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2001;164(8 Pt 1):1414-8.
- 48. Di Francia M, Barbier D, Mege JL, et al. Tumor necrosis factor-alpha levels and weight loss in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 1994;150(5 Pt 1):1453-5.
- 49. Takabatake N, Nakamura H, Abe S, et al. The relationship between chronic hypoxemia and activation of the tumor necrosis factor-alpha system in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2000;161(4 Pt 1):1179-84.
- 50. Langen RC, Schols AM, Kelders MC, et al. Muscle wasting and impaired muscle regeneration in a murine model of chronic pulmonary inflammation. Am J Respir Cell Mol Biol 2006;35(6):689-96.
- 51. Lewis MI, Zhan WZ, Sieck GC. Adaptations of the diaphragm in emphysema. J Appl Physiol 1992;72(3):934-43.
- 52. Marchand E, De Leyn P, Gayan-Ramirez G, et al. Lung volume reduction surgery does not improve diaphragmatic contractile properties or atrophy in hamsters with elastase-induced emphysema. Am J Respir Crit Care Med 2000;162(3 Pt 1):1052-7.
- 53. Degens H, Swisher AK, Heijdra YF, et al. Apoptosis and Id2 expression in diaphragm and soleus muscle from the emphysematous hamster. Am J Physiol Regul Integr Comp Physiol 2007;293(1):R135-44

FIGURE LEGENDS

Figure 1: Mesenchymal stem cells after immunofluorescence staining. (a) CD13 (b) CD29 positive cells (X20)



Eigure 2: The results of flow cytometry analysis of the mesenchymal stem cells. CD29, CD90, CD54 and MHC Class I pozitive; CD45, CD 106 and MHC Class I negative MSCs. These results represent 98.68 of the cells and the positive and negative results for mentioned antigens shows MSCs with very high accuracy and homogeneity.




Figure 3: The histological appearance of the lungs of the rats in the (a) Control group (n=10), (b) Elastase group (n=12), (c) The elastase + MSC group (n=9). Images are representative of 5 images per lung from each animal. Hematoxylin-eosin x 200.




Figure 4: The bar graph of the mean values of the BW changes (0-6 weeks) in the three groups.



Figure 2: The bar graph of the mean values of the BW changes (0-6 weeks) in the three